Diagnostic accuracy of cerebrospinal fluid protein markers for sporadic Creutzfeldt-Jakob disease in Canada: a 6-year prospective study

• Published in: BMC neurology 2011-10, Vol.11 (1), p.133-133, Article 133
• Main Authors: Coulthart, Michael B, Jansen, Gerard H, Olsen, Elina, Godal, Deborah L, Connolly, Tim, Choi, Bernard C K, Wang, Zheng, Cashman, Neil R
• Format: Article
• Language: English
• Subjects: 14-3-3 Proteins - cerebrospinal fluid; Aged; Biological markers; Biomarkers - cerebrospinal fluid; Canada; Cerebrospinal fluid proteins; Cerebrospinal Fluid Proteins - analysis; Creutzfeldt-Jakob disease; Creutzfeldt-Jakob Syndrome - cerebrospinal fluid; Creutzfeldt-Jakob Syndrome - diagnosis; Diagnosis; Evaluation; Female; Humans; Medical research; Middle Aged; Mortality; Nerve Growth Factors - cerebrospinal fluid; Predictive Value of Tests; Prions; Prospective Studies; Proteins; ROC Curve; S100 Calcium Binding Protein beta Subunit; S100 Proteins - cerebrospinal fluid; Sensitivity and Specificity; tau Proteins - cerebrospinal fluid
• ISSN: 1471-2377; 1471-2377
• DOI: 10.1186/1471-2377-11-133

To better characterize the value of cerebrospinal fluid (CSF) proteins as diagnostic markers in a clinical population of subacute encephalopathy patients with relatively low prevalence of sporadic Creutzfeldt-Jakob disease (sCJD), we studied the diagnostic accuracies of several such markers (14-3-3, tau and S100B) in 1000 prospectively and sequentially recruited Canadian patients with clinically suspected sCJD. The study included 127 patients with autopsy-confirmed sCJD (prevalence = 12.7%) and 873 with probable non-CJD diagnoses. Standard statistical measures of diagnostic accuracy were employed, including sensitivity (Se), specificity (Sp), predictive values (PVs), likelihood ratios (LRs), and Receiver Operating Characteristic (ROC) analysis. At optimal cutoff thresholds (empirically selected for 14-3-3, assayed by immunoblot; 976 pg/mL for tau and 2.5 ng/mL for S100B, both assayed by ELISA), Se and Sp respectively were 0.88 (95% CI, 0.81-0.93) and 0.72 (0.69-0.75) for 14-3-3; 0.91 (0.84-0.95) and 0.88 (0.85-0.90) for tau; and 0.87 (0.80-0.92) and 0.87 (0.84-0.89) for S100B. The observed differences in Sp between 14-3-3 and either of the other 2 markers were statistically significant. Positive LRs were 3.1 (2.8-3.6) for 14-3-3; 7.4 (6.9-7.8) for tau; and 6.6 (6.1-7.1) for S100B. Negative LRs were 0.16 (0.10-0.26) for 14-3-3; 0.10 (0.06-0.20) for tau; and 0.15 (0.09-0.20) for S100B. Estimates of areas under ROC curves were 0.947 (0.931-0.961) for tau and 0.908 (0.888-0.926) for S100B. Use of interval LRs (iLRs) significantly enhanced accuracy for patient subsets [e.g., 41/120 (34.2%) of tested sCJD patients displayed tau levels > 10,000 pg/mL, with an iLR of 56.4 (22.8-140.0)], as did combining tau and S100B [e.g., for tau > 976 pg/mL and S100B > 2.5 ng/mL, positive LR = 18.0 (12.9-25.0) and negative LR = 0.02 (0.01-0.09)]. CSF 14-3-3, tau and S100B proteins are useful diagnostic markers of sCJD even in a low-prevalence clinical population. CSF tau showed better overall diagnostic accuracy than 14-3-3 or S100B. Reporting of quantitative assay results and combining tau with S100B could enhance case definitions used in diagnosis and surveillance of sCJD.